drugset / Trial / NCT02585973
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
NaSingle-groupOpen-labelTreatment
Summary
This open label, single-arm, Phase 1b study is designed to identify the maximum tolerated dose (MTD) using a traditional 3+3 dose escalation design of the WEE-1 inhibitor AZD1775 when added to standard of care chemotherapy (cisplatin) and radiation for the treatment of locally advanced squamous cell cancer of the head and neck (HNSCC).
Timeline
- Start
- 2015-10-26
- Primary completion
- 2019-06-14
- Completion
- 2021-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adavosertib | Small molecule | 50 mg | — |
| Subject | Adavosertib | Small molecule | 100 mg | — |
| Subject | Adavosertib | Small molecule | 150 mg | — |
| Subject | Adavosertib | Small molecule | 200 mg | — |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |